NEW YORK (GenomeWeb News) – Investment bank Cowen and Co. has downgraded the stocks of Luminex and Qiagen to Underperform from Neutral.

Analysts Doug Schenkel and Shaun Rodriguez wrote in a research note published today that concerns about competition and a lack of "significant near-term catalysts" has led them to downgrade Luminex. "We believe competitive pressures have intensified for [Luminex's] molecular diagnostics franchise and anticipate pronounced share loss in [Respiratory Virus Panel] and a muted [Gastrointestinal Pathogen Panel] launch as a result."

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

NPR reports that with medical data being big business, some companies want to get patients involved.

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.

Nov
07
Sponsored by
Qiagen

This webinar will provide a first-hand look at how a leading pathology lab implemented a next-generation sequencing panel to capture comprehensive molecular tumor profiles.

Nov
29
Sponsored by
Schott

This webinar will discuss how understanding the relative performance characteristics of glass and polymer substrates for in vitro diagnostic applications such as microarrays and microfluidics can help to optimize diagnostic performance.